BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Macrogen Inc.

Headquarters: Seoul, South Korea
Year Founded: 1997
Status: Public
Industry Sector: HealthServices
CEO: Chang-Hoon Kim, PhD; Jeong-Sun Seo, PhD
Number Of Employees: 529
Enterprise Value: $148,756,225
PE Ratio: -25.39
Exchange/Ticker 1: KOSDAQ:038290
Exchange/Ticker 2: N/A
Latest Market Cap: $119,743,647

BioCentury | Nov 18, 2022
Regulation

Nov. 17 Quick Takes: FDA approves Provention’s mAb to slow onset of diabetes

Plus: Rezo’s launch, deals by Regeneron-CytomX and Marinus-Tenacia, the end of a GSK-Immatics deal, and Tenaya’s funding
BioCentury | Oct 18, 2022
Deals

Oct. 17 Quick Takes: Gilead, MacroGenics in deal for bispecific

Biogen’s ALS candidate delayed, plus updates from Oculis, Treeline, Minerva, Acrivon and more
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

Why there’s a gap in standards research for somatic cell versus germline editing
BioCentury | Apr 28, 2016
Finance

Public-Private Partnership Roundup

Highlights of public-private partnerships from 1Q16
BioCentury | Jan 20, 2014
Company News

Illumina sales and marketing update

BioCentury | Jan 15, 2014
Company News

Illumina introduces $1,000 human genome system

BioCentury | Mar 1, 2012
Cover Story

REThinking lung cancer

BioCentury | Aug 2, 2010
Company News

Illumina sales and marketing update

BioCentury | Jul 9, 2001
Company News

Macrogen Inc. other research news

Items per page:
1 - 10 of 10
Help Center
Username
Request Training
Submit Data Correction
Ask a Question